MENU
+Compare
ANAB
Stock ticker: NASDAQ
AS OF
Nov 21, 11:54 AM (EDT)
Price
$35.87
Change
-$1.79 (-4.75%)
Capitalization
1.04B

ANAB AnaptysBio Forecast, Technical & Fundamental Analysis

AnaptysBio Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
ANAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ANAB with price predictions
Nov 20, 2025

Aroon Indicator for ANAB shows an upward move is likely

ANAB's Aroon Indicator triggered a bullish signal on November 11, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator showed a similar pattern. In of the 189 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ANAB moved out of overbought territory on November 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ANAB as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ANAB turned negative on October 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ANAB broke above its upper Bollinger Band on November 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.301) is normal, around the industry mean (27.115). P/E Ratio (0.000) is within average values for comparable stocks, (51.613). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.036). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (6.545) is also within normal values, averaging (317.729).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ANAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ANAB is expected to report earnings to rise 18.08% to 61 cents per share on March 09

AnaptysBio ANAB Stock Earnings Reports
Q4'25
Est.
$0.61
Q3'25
Beat
by $1.92
Q2'25
Beat
by $0.18
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.90
The last earnings report on November 04 showed earnings per share of 51 cents, beating the estimate of -139 cents. With 320.87K shares outstanding, the current market capitalization sits at 1.04B.
A.I. Advisor
published General Information

General Information

a provider of therapeutic antibodies for inflammation and immuno-oncology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10770 Wateridge Circle
Phone
+1 858 362-6295
Employees
117
Web
https://www.anaptysbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLHIX28.36N/A
N/A
Macquarie Healthcare I
DGYGX40.53N/A
N/A
BNY Mellon Appreciation Y
NPNAX51.43N/A
N/A
Neuberger Berman Large Cap Value A
DSCIX14.95N/A
N/A
Dana Epiphany Small Cap Eq Instl
FIFQX24.23N/A
N/A
Fidelity Advisor Founders C

ANAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with QTTB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+1.81%
QTTB - ANAB
40%
Loosely correlated
-8.96%
IBRX - ANAB
40%
Loosely correlated
-5.37%
CLRB - ANAB
40%
Loosely correlated
-1.75%
AMRN - ANAB
38%
Loosely correlated
-3.24%
ZURA - ANAB
37%
Loosely correlated
-5.17%
More